Tuesday, 17 Sep 2019

You are here

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Noting studies that showed premature mortality among ESRD lupus nephritis patients, researchers set out to examine if these trends have continued. Using national registry data through 2014, they studied 20,974 patients with incident ESRD due to LN between January 1, 1995 and December 31, 2014 and examined outcomes in 5-year blocks (1995–1999, 2000–2004, 2005–2009, 2010–2014).

Between 1995 through 2014, the mortality rate per 100 patient- years declined steadily:

  • 1995–1999 - 11.1 (95% confidence interval [95% CI] 10.4–11.8)
  • 2010–2014 - 6.7 (95% CI 6.2–7.2) (P trend < 0.01).

Compared with 1995–1999, the adjusted mortality hazard ratios in 2010–2014 were lower for whites (0.68;0.58–0.78), African Americans (0.67; 0.57–0.78), and for Hispanics (0.51; 0.38–0.69).

Deaths from cardiovascular disease (CVD) and infection declined by 44% and 63%, over this same period (p< 0.01 for both).

It appears that improving care in this high- risk population has lead to a reduction in all- cause mortality among white, African American, and Hispanic patients, with reduced risk of death from CVD and infection. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).